Allianz Asset Management GmbH Decreases Stock Position in Haemonetics Corporation $HAE

Allianz Asset Management GmbH lessened its position in Haemonetics Corporation (NYSE:HAE) by 11.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,240 shares of the medical instruments supplier’s stock after selling 563 shares during the quarter. Allianz Asset Management GmbH’s holdings in Haemonetics were worth $316,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in HAE. KBC Group NV lifted its position in shares of Haemonetics by 19.9% in the first quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier’s stock valued at $154,000 after acquiring an additional 401 shares in the last quarter. Vontobel Holding Ltd. lifted its position in shares of Haemonetics by 21.7% in the first quarter. Vontobel Holding Ltd. now owns 15,839 shares of the medical instruments supplier’s stock valued at $1,007,000 after acquiring an additional 2,828 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in shares of Haemonetics in the first quarter valued at approximately $467,000. Principal Financial Group Inc. lifted its position in shares of Haemonetics by 1.4% in the first quarter. Principal Financial Group Inc. now owns 158,894 shares of the medical instruments supplier’s stock valued at $10,098,000 after acquiring an additional 2,160 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of Haemonetics by 16.0% in the first quarter. Envestnet Asset Management Inc. now owns 55,746 shares of the medical instruments supplier’s stock valued at $3,543,000 after acquiring an additional 7,678 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

HAE stock opened at $50.37 on Wednesday. The business has a fifty day moving average of $51.58 and a two-hundred day moving average of $62.31. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. The stock has a market cap of $2.43 billion, a price-to-earnings ratio of 15.40, a price-to-earnings-growth ratio of 0.94 and a beta of 0.37. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $94.99.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.09. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The company had revenue of $321.39 million during the quarter, compared to analysts’ expectations of $305.12 million. During the same quarter last year, the firm earned $1.02 earnings per share. The firm’s quarterly revenue was down 4.4% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, research analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Citigroup reduced their price objective on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. Barrington Research reiterated an “outperform” rating and set a $86.00 price objective on shares of Haemonetics in a research report on Tuesday, October 21st. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $62.00 price objective (down previously from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Raymond James Financial downgraded Haemonetics from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the stock from $105.00 to $78.00 in a research report on Monday, August 11th. Finally, Weiss Ratings downgraded Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $75.89.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.